DMDG 2026
Event:
Date: October 7, 2026
Venue: Europe,Prague
We aspire to advance the frontiers of science with our partners, delivering solutions that bring innovative medicines to patients worldwide.
Science-led, execution focused
Sai Life Sciences is one of India’s fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO). We partner with pharmaceutical and biotechnology innovators to advance novel drug programs from discovery to commercial manufacturing—combining scientific rigor, operational excellence, and speed across the value chain.
Built on Experience
Years of expertise
0
+
R&D and manufacturing sites
across US, UK, and India
0
Regulatory inspection success across R&D, manufacturing sites
0
%
Scientists and professionals
0
+
Active customers across US, UK, EU & Japan
0
+
of the largest pharma companies are our customers
0
/25
of discovery portfolio constituted by integrated programs
0
%
Active NCE Commercial/ Phase III/ Pre-registration molecules
0
Support at every stage
We deliver capabilities across the drug development continuum to support your program at every stage—enabling faster progression with clarity as complexity increases.
End-to-End by Capability.
We deliver capabilities across the drug development continuum to support your program at every stage—enabling faster progression with clarity as complexity increases.
Target Validation to Your Lead Candidate
Lead identified to First-in-Human Trials
Early Phase (FTIH) to Late Phase (pivotal supplies)
Late Phase through to Validation & Filing
Life Cycle Management of Commercialized Products
Target Validation to Your Lead Candidate
Lead identified to First-in-Human Trials
Early Phase (FTIH) to Late Phase (pivotal supplies)
Late Phase through to Validation & Filing
Life Cycle Management of Commercialized Products
Discovery to Delivery for Small Molecules and Beyond
Discovery
Integrated discovery services across medicinal and synthetic chemistry, biology, DMPK, and toxicology—advancing programs from target validation to lead candidates through structured design, make, test and analyse (DMTA) cycles.
Formulations
Phase-appropriate formulation development across oral, parenteral, and specialty dosage forms—supporting timely clinical and commercial supply.
New Modalities
Specialized development and manufacturing expertise for complex modalities, including ADCs, peptides, lipids, and oligonucleotides—enabling scalable execution from early development onward.
Upcoming Events
CPHI Milan
Event:
Date: October 8, 2026
Venue: Europe,Milan - Italy
World ADC
Event:
Date: October 12-15, 2026
Venue: San Diego, CA
New research sheds light on how therapeutic antibodies and ADCs are processed inside cells
Understanding what happens to therapeutic antibodies and antibody-drug conjugates (ADCs) after they enter a cell is critical to designing targeted […]
Sai Life Sciences plans new oral solid formulation facility
Sai Life Sciences plans to set up a new oral solid formulation facility to support small-molecule programs entering early clinical […]
Flow chemistry advances from development into GMP manufacturing
We have successfully scaled up a late-stage GMP intermediate for a large pharmaceutical customer using flow chemistry, marking another step […]
Advancing 3D Hepatic Spheroid-Array Approach for Hepatic Clearance Assessment
A recent publication from Sai Life Sciences highlights our work on a three-dimensional hepatic spheroid-array system for the assessment of […]
Deepening customer partnerships through FTE models
Sai Life Sciences is seeing increasing opportunities to deepen and expand customer relationships through dedicated Full-Time Equivalent (FTE) engagement models, […]
First phase of Sai Life Sciences’ new integrated R&D Campus now open
Sai Life Sciences has inaugurated the first facility within its new Unit VIII campus in Hyderabad’s Genome Valley, marking an […]
Global Footprint
Bidar, India
Unit 4 – API Manufacturing Facility
Unit 6 – Animal Health API Manufacturing Facility